Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33:488-499.
PMID: 35124183